BUMETANIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bumetanide, and when can generic versions of Bumetanide launch?
Bumetanide is a drug marketed by Anthea Pharma, Aspiro, Gland, Hospira, Lupin, MSN, Qilu Pharm Hainan, Sagent, Teva Parenteral, West-ward Pharms Int, Amneal Pharms Co, Appco, Heritage Pharma, Jubilant Generics, Mankind Pharma, Rising, Rubicon Research, Sandoz, Taro, Upsher Smith Labs, and Zydus Pharms. and is included in twenty-three NDAs.
The generic ingredient in BUMETANIDE is bumetanide. There are six drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the bumetanide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bumetanide
A generic version of BUMETANIDE was approved as bumetanide by SAGENT on January 27th, 1995.
US Patents and Regulatory Information for BUMETANIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taro | BUMETANIDE | bumetanide | TABLET;ORAL | 213458-003 | Jul 24, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Rising | BUMETANIDE | bumetanide | TABLET;ORAL | 212019-003 | Dec 12, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Pharms | BUMETANIDE | bumetanide | TABLET;ORAL | 202900-001 | Apr 30, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
